Tag Archives: Pfizer
By Ben Comer | Published: November 14, 2012
How can the emerging field of data science help to fruitfully translate research and discovery into successful drug development? Academics and pharmaceutical executives at Mount Sinai’s School of Medicine discussed ways to build a bridge across the valley of death, and the growing importance of data across all business areas.
By Guest Blogger | Published: September 21, 2012
By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
By Julian Upton | Published: February 2, 2012
UK Waits for AZ Job Cut Breakdown As this blog was posted, AstraZeneca was still keeping the world in suspense as to a further breakdown of its announced 7,300 job cuts. The company’s UK staff assembled for a meeting at 10 am, but as of lunchtime there was still no confirmation of the actual numbers , [...]
By Guest Blogger | Published: September 21, 2011
Deals don’t need science to be a success By Brian McGilligan, Partner, Pharmaceutical Practice, PIPC Ex Pfizer R&D boss, John L. LaMattina recently proclaimed that Big Pharma mergers are crippling science. Whether or not you agree, mergers are a core part of business and the chances of safe-guarding future R&D investment in merged companies will best be [...]